奥卡西平缓释片立项报告

SUSTAINED ACTION 10MG TITANIUM DIOXIDE ORAL; TABLET, SUSTAINED ACTION, COATED 4.17MG TITANIUM DIOXIDE ORAL; TABLET, SUSTAINED ACTION, FILM COATED 3MG 6. 制剂工艺未查到 7. 原料药合成路线见专利 8. 原料药杂质信息(列出以下可获得信息以及杂质来源信息) 美国药典英国药典欧洲药典杂质属性(降解、氧化产物、中间体等) Acridine-9-carboxy lic acid. ; 无 A.5 -dibenzo[ ]azepine-5-carboxam ide (carbamazepine 10,11-Dioxo-10,11 -dihydro-5H-diben zo[b,f]azepine-5-ca rboxamide. Acridin-9(10H)-one ; N-Formyl-10-oxo-1 0,11-dihydro-5H-d ibenzo[b,f]azepine- 5-carboxamide B. 10-methoxy-5 -dibenzo[ ]azepine-5-carboxam ide (10-methoxycarbamazepine), 9 C. 5,11-dihydro-10 -dibenzo[ ]azepin-10-one, F. 10-methoxy-5 -dibenzo[ ]azepine-5-carbonyl chloride E.5 -dibenzo[ ]azepine 10 D.5 -dibenzo[ ]azepine-10,11-dione , G. 5-ethyl-10-methoxy-5 -dibenzo[ ]azepine H. 10-methoxy-5 -dibenzo[ ]azepine,